Raunak Shrestha, PhD
Title
Cited by
Cited by
Year
Pan-cancer analysis of whole genomes
I The, TPCA of Whole, Genomes Consortium
Nature 578 (7793), 82, 2020
5692020
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
E Rheinbay, MM Nielsen, F Abascal, JA Wala, O Shapira, G Tiao, ...
Nature 578 (7793), 102-111, 2020
2282020
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
AW Wyatt, F Mo, K Wang, B McConeghy, S Brahmbhatt, L Jong, ...
Genome biology 15 (8), 1-14, 2014
842014
BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma
R Shrestha, N Nabavi, YY Lin, F Mo, S Anderson, S Volik, HH Adomat, ...
Genome Medicine 11 (1), 8, 2019
482019
Pathway and network analysis of more than 2500 whole cancer genomes
MA Reyna, D Haan, M Paczkowska, LPC Verbeke, M Vazquez, ...
Nature Communications 11 (1), 1-17, 2020
462020
Ultra high-dimensional nonlinear feature selection for big biological data
M Yamada, J Tang, J Lugo-Martinez, E Hodzic, R Shrestha, H Ouyang, ...
IEEE Transactions on Knowledge and Data Engineering, 2018
452018
HIT'nDRIVE: Patient-specific multi-driver gene prioritization for precision oncology
R Shrestha, E Hodzic, T Sauerwald, P Dao, K Wang, J Yeung, ...
Genome Research, 2017
322017
High-throughput detection of RNA processing in bacteria
EE Gill, LS Chan, GL Winsor, N Dobson, R Lo, SJH Sui, BK Dhillon, ...
BMC genomics 19 (1), 1-20, 2018
282018
BIRC6 targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer
ISU Luk, R Shrestha, H Xue, Y Wang, F Zhang, D Lin, A Haegert, R Wu, ...
Clinical Cancer Research 23 (6), 1542-1551, 2017
262017
HIT’nDRIVE: Multi-Driver Gene Prioritization based on Hitting Time
R Shrestha, E Hodzic, J Yeung, K Wang, T Sauerwald, P Dao, ...
132014
A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines
K Wang, R Shrestha, AW Wyatt, A Reddy, J Lehár, Y Wang, A Lapuk, ...
PLoS One 9 (7), e103050, 2014
112014
Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma
NM D’Costa, MR Lowerison, PA Raven, Z Tan, ME Roberts, R Shrestha, ...
Journal of Experimental & Clinical Cancer Research 39 (1), 1-16, 2020
92020
Deep Genomic Signature for early metastasis prediction in prostate cancer
H Sharifi-Noghabi, Y Liu, N Erho, R Shrestha, M Alshalalfa, E Davicioni, ...
BioRxiv, 276055, 2019
82019
Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma
NM D’Costa, D Cina, R Shrestha, RH Bell, YY Lin, H Asghari, ...
Scientific Reports 10 (1), 1-9, 2020
62020
Combinatorial Detection of Conserved Alteration Patterns for Identifying Cancer Subnetworks
E Hodzic, R Shrestha, K Zhu, K Cheng, CC Collins, SC Sahinalp
GigaScience 8 (4), 369850, 2019
62019
Autoantibody landscape in patients with advanced prostate cancer
WS Chen, WA Haynes, R Waitz, K Kamath, A Vega-Crespo, R Shrestha, ...
Clinical Cancer Research 26 (23), 6204-6214, 2020
52020
Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma
R Shrestha, N Nabavi, S Volik, S Anderson, A Haegert, B McConeghy, ...
Cancers 12 (6), 2020
52020
Analysis of KatG Ser315Thr Mutation in Multidrug Resistant Mycobacterium tuberculosis and SLC11A1 Polymorphism in Multidrug Resistance Tuberculosis in Central Development …
R Shrestha, RN Joshi, K Joshi, BH Poudel, BG Shrestha
Nepal Journal of Biotechnology 1 (1), 14-21, 2011
52011
Identification of Conserved Evolutionary Trajectories in Tumors
E Hodzic, R Shrestha, S Malikic, CC Collins, K Litchfield, S Turajlic, ...
Bioinformatics 36 (Supplement_1), i427-i435, 2020
32020
Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability
R Shrestha, ML Fernandez, A Dawson, J Hoenisch, S Volik, YY Lin, ...
Cancer Research, 2021
12021
The system can't perform the operation now. Try again later.
Articles 1–20